
FDA Expands Approval of VONVENDI for Von Willebrand Disease in Adults and Children
FDA Expands Approval of Takeda’s VONVENDI®, First Recombinant von Willebrand Factor Therapy, to Include Routine Prophylaxis for Adults and Children with von Willebrand Disease Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK), a…












